The Board created 150,000 subscription rights under a new plan on November 10, 2026, to compensate current and future employees. Each right allows subscribing to one new share.
LKFT · Lakefront Biotherapeutics NV
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 85%
- Last earnings
- Nov 11, 2026
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
Lakefront says it is preparing registrational studies of Gamgertamig in ITP and WAIHA, possibly starting in 2027, and holds 2.2 billion euros in cash.
Lakefront Biotherapeutics NV initiated a share repurchase program of up to €50 million, covering up to 4,604,550 ordinary shares, beginning November 16, 2026 and ending on the earlier of March 31, 2027 or mandate completion.
Lakefront reported €13.9 million net profit for the first nine months of 2026 and expects year-end 2026 cash and financial investments of €2.0 to €2.05 billion, including a second €50 million share repurchase program.
Lakefront Biotherapeutics NV will host a fireside chat at the 2026 Jefferies Global Healthcare Conference in London at 2:00 pm GMT (9:00 am ET) on Tuesday, November 17, 2026.
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LKFT
this stock
Lakefront Biotherapeutics NV
|
$2.20B | +2.1% | — | — | 2.0% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$132.01B | +14.8% | +46.2% | 33.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.52B | +19.6% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$80.65B | +575.9% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.36B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 18, 2026
- This year
- 57
The Board created 150,000 subscription rights under a new plan on November 10, 2026, to compensate current and future employees. Each right allows subscribing to one new share.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LKFT | -1.6% | +6.3% | +21.2% | +3.4% | +2.1% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | +3.9% | +12.6% | +26.9% | +8.7% | -2.9% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.